Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCFinancial_Report.xls
10-Q - FORM 10-Q - HI TECH PHARMACAL CO INCd399017d10q.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR7.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR6.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR8.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR2.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR5.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR3.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR4.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR1.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR9.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR49.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR23.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR40.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR38.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR27.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR34.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR50.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR28.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR17.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR16.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR48.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR55.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR37.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR56.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR31.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR29.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR15.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR32.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR13.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR54.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR10.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR43.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR18.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR53.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR12.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR35.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR36.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR19.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR42.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR24.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR45.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR25.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR46.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR20.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR41.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR22.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR11.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR39.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR47.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR26.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR44.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR30.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR14.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR52.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR33.htm
XML - IDEA: XBRL DOCUMENT - HI TECH PHARMACAL CO INCR51.htm
EX-32 - EX-32 - HI TECH PHARMACAL CO INCd399017dex32.htm
EX-31.2 - EX-31.2 - HI TECH PHARMACAL CO INCd399017dex312.htm
EX-31.1 - EX-31.1 - HI TECH PHARMACAL CO INCd399017dex311.htm
v2.4.0.6
Recent Accounting Pronouncements
6 Months Ended
Oct. 31, 2012
Recent Accounting Pronouncements [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS

15. RECENT ACCOUNTING PRONOUNCEMENTS:

In July 2012, the FASB issued accounting guidance to simplify the testing for a drop in value of indefinite-lived intangible assets. Under the updated guidance, an entity has the option of first performing a qualitative assessment to determine whether it is more likely than not that an indefinite-lived intangible asset is impaired before proceeding to the quantitative impairment test under which it would calculate the asset’s fair value. When performing the qualitative assessment, the entity must evaluate events and circumstances that may affect the significant inputs used to determine the fair value of the indefinite-lived intangible asset. This guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the Company’s results of operations, cash flows or financial position.